Drugs for type 2 diabetes.
D001645:Biguanides / Q000627:therapeutic use; D002219:Carbamates / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D000519:alpha-Galactosidase / Q000037:antagonists & inhibitors
D001645:Biguanides; D002219:Carbamates; D003510:Cyclohexanes; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D007328:Insulin; D010880:Piperidines; D011719:Pyrazines; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; D014230:Triazoles; D000077715:Nateglinide; D010649:Phenylalanine; C072379:repaglinide; D000519:alpha-Galactosidase; D000068900:Sitagliptin Phosphate